Jazz Pharmaceuticals plc — Q2 2023 Form 10-Q
Business context and period. Global biopharmaceutical company focused on neuroscience and oncology, with marketed products including Xywav, Xyrem, Epidiolex/Epidyolex, Rylaze, Zepzelca, Defitelio and Vyxeos. This unaudited report covers the quarter and six months ended June 30, 2023; comparisons are with the corresponding 2022 periods.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $957.3 million | $932.9 million | $1,850.1 million | $1,746.6 million |
| Operating income | $157.6 million | $85.5 million | $283.7 million | $173.1 million |
| Net income | $104.4 million | $34.7 million | $173.9 million | $36.3 million |
| Diluted EPS | $1.52 | $0.55 | $2.55 | $0.57 |
| Gross margin on product sales | 89.7% | 86.6% | 87.6% | 86.2% |
- Revenue mix and changes: Q2 product sales rose 2%; royalties and contract revenue were $10.3 million, including $5.5 million from high-sodium oxybate authorized-generic sales. Xywav revenue increased 39% to $326.6 million, while Xyrem fell 41% to $159.8 million. Epidiolex/Epidyolex increased 15% to $202.2 million and Rylaze increased 39% to $101.7 million. Total oncology sales rose 10%; Defitelio/defibrotide declined 16% to $46.1 million. The U.S. accounted for $884.7 million of Q2 revenue.
- Expenses and profitability: Q2 R&D expense increased 50% to $209.2 million, mainly from clinical development programs. SG&A declined 7% to $340.8 million. Operating income and net income increased year over year; the comparison includes $69.1 million of acquired in-process R&D expense in Q2 2022 that did not recur in Q2 2023. Net interest expense rose 16% to $73.5 million, primarily due to higher term-loan rates.
- Cash flow: Six-month operating cash flow was $617.5 million, versus $512.0 million. Investing used $90.6 million and financing used $126.5 million. Cash and cash equivalents increased $400.8 million to $1,282.3 million.
- Liquidity and debt: At June 30, cash, cash equivalents and investments totaled $1.362 billion; the company also reported $500 million of revolving-credit availability. Debt principal was approximately $5.813 billion, with $5.718 billion carrying value. Cash and investments less debt principal imply net debt of approximately $4.451 billion. Current liabilities were $945.3 million and current assets $3.010 billion.
- Capital allocation: The company repurchased $95.6 million of shares during the first half at an average $126.37 per share; $335.6 million remained authorized at June 30.
Material changes, outlook and management commentary
- Management expects 2023 total product sales to exceed 2022, driven by continued Xywav growth, Epidiolex and oncology products, partly offset by Xyrem declines. It expects royalty and contract revenue to rise, cost of product sales and SG&A to decline, R&D expense to increase, and net interest expense to increase. The filing provides no specific numerical full-year guidance in the supplied text.
- Xywav growth reflects patient transition from Xyrem and uptake in idiopathic hypersomnia. Xyrem sales are pressured by this transition and authorized-generic competition. Average active oxybate patients were approximately 16,200 in Q2, down about 5% year over year; approximately 11,500 were taking Xywav at quarter end.
- Competition is intensifying: Avadel’s Lumryz was FDA-approved in May 2023; an additional authorized generic entered the market in July 2023. Jazz disputes FDA’s Lumryz approval and filed suit. Generic applicants also challenge patents covering Xyrem, Xywav and Epidiolex.
- Pipeline and regulatory developments include continued development of zanidatamab and other candidates; FDA requested additional clinical data for Rylaze IV administration, without affecting the approved intramuscular label. Management anticipated European Commission approval for Rylaze in 2023.
Risks, contingencies and unusual items
- Commercial concentration and pricing: The company remains meaningfully dependent on oxybate revenue. Generic and branded competition, payer coverage changes, rebates, price pressure and adoption of Xywav could affect sales. ESSDS represented 51% of total revenue in both Q2 and the first half; five customers represented 81% of gross receivables at June 30.
- Legal matters: Xyrem purchaser antitrust litigation received preliminary class certification; plaintiffs seek monetary and injunctive relief. Jazz is also involved in Avadel oxybate patent and trade-secret litigation, Xywav and Epidiolex patent cases, an MSP lawsuit, and litigation challenging FDA’s Lumryz approval. Outcomes and potential financial exposure are uncertain; the filing does not provide a clear quantified loss estimate for these matters.
- Other risks: The filing cites substantial debt, dependence on single-source suppliers, clinical and regulatory uncertainty, reimbursement and drug-pricing policy, and intellectual-property protection. A Luxembourg tax assessment of approximately $24.3 million is being contested.
- Unusual reported item: Q2 2022 included $69.1 million of acquired in-process R&D expense. The first half of 2023 included $1.0 million of such expense. Foreign-currency translation contributed $253.8 million of other comprehensive income in the first half of 2023.
Important facts for investors to verify
- Whether Xywav growth offsets continuing Xyrem volume declines and new oxybate competition.
- Progress and commercial impact of authorized generics, Lumryz, and potential generic launches affecting Xyrem, Xywav and Epidiolex.
- Execution of pipeline and regulatory milestones, including Rylaze IV data and zanidatamab development.
- Debt service, refinancing and deleveraging progress in light of $5.8 billion of debt principal and rising interest expense.
- Developments in the antitrust, patent, FDA-approval and tax matters, including any changes to estimated exposure.